37
Participants
Start Date
May 8, 2023
Primary Completion Date
February 22, 2027
Study Completion Date
February 22, 2027
Osimertinib
Osimertinib (dose range of 40 mg to 240 mg orally, once daily)
Research Site, Taoyuan District
Research Site, Tainan City
Research Site, Tainan City
Research Site, Seoul
Research Site, Goyang-si
Research Site, George Town
Research Site, Seongnam-si
Research Site, Kuantan
Research Site, Cheongju-si
Research Site, Taichung
Research Site, Donggu
Research Site, Johor Bahru
Research Site, Kaohsiung City
Research Site, Kuching
Research Site, Villejuif
Research Site, Beijing
Research Site, Taipei
Research Site, Shanghai
Research Site, Yangzhou
Research Site, Chongqing
Research Site, Zhengzhou
Research Site, Szczecin
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Nottingham
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY